Switching genes off without cutting them
Normal gene editing cuts DNA. This switches a gene off and leaves it intact. Hepatitis B is simply the first disease it is being tried on.
35%likely
Single source
Next check
Watching
Why it is different
The bet is on the method of switching genes off reversibly, not on the hepatitis drug that happens to be testing it first.
Why it matters
If it holds up in people it opens a whole class of medicines, far beyond this one disease.
Next check · 30 Jun 2027
Is a second-stage trial of TUNE-401 registered and recruiting patients on or before 30 Jun 2027?
How we scored it ·
from how similar cases went
If right, how big5/5How overlooked5/5Upside vs downside4/5Source trust3/5Independent sources1/5
The exact wording we score
In-vivo epigenetic silencing validates clinically by end-2030: a qualifying silencer shows durable off-treatment target silencing in a controlled trial.